Compare Tango Therapeutics Inc. (TNGX) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Vanguard Value Index Fund ETF — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B), while Vanguard Value Index Fund ETF trades at $221.56 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 70.2× Tango Therapeutics Inc.'s market cap, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Vanguard Value Index Fund ETF for 143 Days on average.
| TNGX | VTV | |
|---|---|---|
Market Cap | $3.74B | $262.40B |
Volume | 3,438,781 | 2,800,630 |
Sector | Health | — |
52-Week High | $32.90 | $227.51 |
52-Week Low | $7.50 | $182.89 |
Typical Hold Time | 0 Days | 143 Days |
Enterprise Value | $2.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
VTV trades at $220.67, down 0.34% on the day, with a bullish technical signal supported by moving averages but mixed oscillators. The ETF shows strong institutional interest with recent acquisitions by QRG Capital Management and Blue Edge Capital. Recent news highlights VTV's 2.3% dividend yield and value-focused strategy outperforming growth counterparts in 2026, with value stocks gaining traction amid market rotation away from tech concentration.
VTV presents a compelling value proposition with low 0.03% fees and income appeal, though long-term performance trails the S&P 500. Key risks include sustained growth stock dominance and interest rate sensitivity. The ETF's diversification across value stocks positions it well for investors seeking stability amid market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
